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Abstract 
In this stressful era, maintaining the proper balance of neuronal excitation and inhibition 
remains the central demand of human brain. To harmonize the optimal brain functioning, γ-
Amino Butyric Acid type A Receptors (GABAA-Rs) play a vital role by mediating the fast 
inhibitory neurotransmissions. These GABA-gated chloride ion channels maintain the 
delicate balance between neuronal excitation and inhibition. The formation of GABAA-R 
uses repertoire of 19 different subunit subtypes α1-6, β1-3, γ1-3, δ, ε, π, θ and ρ1-3, out of which 
two α1, two β2 and one γ2 form the most abundant native GABAA-R structure. In the absence 
of heteropentameric human GABAA-R structure the structural biology remains yet to be fully 
explored. Manipulation of GABAergic transmission is aimed to provide the benefits in the 
treatment of a host of neurological and psychiatric disorders. We utilised the existing 
experimental data and carried out a computational study to obtain the structural details of 
different GABAA-Rs. This computational pathway sequentially proceeds for : i) obtaining the 
different GABAA-R states and subtypes; ii) understanding the logic of their existence and 
correlating structure-function details for each of them; iii) unravelling the complete journey 
of molecular events that fine tune the state dependent channel transitions in normal 
conditions including ligand unoccupied closed, open, uncapped receptive states and GABA 
occupied singly and doubly bound states; iv) understanding the nature of cross-talk between 
two orthosteric sites and third allosteric BZD-site when we brought it into consideration;                
v) identifying a set of governing rules/markers forming the structural basis of selective 
modulation for BZD-site agonists at α1- and α2-GABAA-R subtypes.  
Accordingly, to fulfil the deliberate demand of clinically efficacious α2-selective non-sedative 
modulator/s the underlying logic is systematically demarcated under single platform. The 
crux from the early stage modulatory pathways of subtype selective actions provides newer 
avenues to guide the designing of novel modulator/s having desired pharmacological 
endpoints in diseased states.       
Overall, this channelled study is bound to track the structure-function-novel drug designing, 
based on the understanding of GABAA-R modulatory pathways.  
